Carpenter Technology Corporation
Recent
price
P/E
ratio
div
yld
0.22%
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Carpenter Technology Corporation (NYSE: CRS) manufactures and distributes premium specialty alloys, stainless steels, nickel, cobalt, titanium, and superalloys, as well as metal powders for additive manufacturing and precision engineered components; its core offerings encompass high-temperature superalloys, high-strength steels, implantable and biocompatible alloys, controlled expansion alloys, tool and die steels, titanium products including wire, bar, strip and shaped components, gas-atomized pre-alloyed powders, and custom parts with value-added services such as contract manufacturing and alloy conversion. The company operates through two primary segments: Specialty Alloys Operations, which produces premium alloys and stainless steels at facilities in the United States, Europe, and Asia; and Performance Engineered Products, which includes titanium manufacturing via Dynamet Incorporated, additive manufacturing through Carpenter Additive, powder production, and distribution services across the U.S., Canada, Mexico, North America, and South America. These products serve critical applications in aerospace and defense (including engines, landing gear, and precision components), medical (prosthetics, surgical instruments, and orthopedics), transportation, energy (power generation, oil and gas), industrial, consumer goods, and electrification markets. Founded in 1889 and headquartered in Philadelphia, Pennsylvania, with key manufacturing sites in Reading, Pennsylvania; Tanner, Alabama; and Hartsville, South Carolina, the company targets high-performance needs in mission-critical sectors globally. In recent developments, Carpenter Technology closed a $700.0 million private offering of 5.625% senior notes due 2034 in November 2025 and amended its credit agreement to expand revolving commitments from $350 million secured to $500 million unsecured, extending maturity to 2030 with an accordion feature up to $650 million. The company continues a major brownfield expansion project at its Athens, Alabama facility to increase primary and secondary melt capacity, with construction underway, on schedule and budget, and capital spending accelerating in fiscal 2026 to support aerospace demand growth. Strong fiscal 2025 and first quarter 2026 results reflect record operating income, robust aerospace and defense revenue exceeding 60% of total (up sequentially and year-over-year), share repurchases totaling over $150 million under a $400 million authorization, and optimistic guidance for $660-$700 million operating income in fiscal 2026 and $765-$800 million in 2027 driven by multi-year demand in key markets.
Company News
Carpenter Technology Reports First Quarter Fiscal Year 2027 Results
IIIN vs. CRS: Which Stock Is the Better Value Option?
Gear Up for Carpenter (CRS) Q1 Earnings: Wall Street Estimates for Key Metrics
Will Carpenter (CRS) Beat Estimates Again in Its Next Earnings Report?
Carpenter Technology Set to Report Q1 Earnings: What to Expect?
Carpenter Technology Corporation Announces General Counsel Succession
Carpenter Technology: I Called The Sell, Now It's A Buy
After Plunging 13.0% in 4 Weeks, Here's Why the Trend Might Reverse for Carpenter (CRS)
Benzinga's 'Stock Whisper' Index: Five Stocks Investors Secretly Monitor But Don't Talk About Yet
Carpenter Technology Declares Quarterly Cash Dividend
What Makes Carpenter (CRS) a New Buy Stock
Is CRS Set to Gain From Growth in Its Specialty Alloys Operations?
Carpenter Technology Touts Record Fiscal 2026 Earnings, Capacity Expansion at Annual Meeting
6,806 Carpenter Technology Corporation $CRS Shares Sold by Tompkins Financial Corp
Poolbeg secures South Korean cancer immunotherapy-induced CRS patent
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell
Carpenter Technology Announces Conference Call and Webcast
Carpenter Technology (CRS) is a Top-Ranked Growth Stock: Should You Buy?
Our Top 10 High Growth Dividend Stocks - September 2026